Valerie DeBenedette
Valerie DeBenedette is Managing Editor of Drug Topics.
Use of insulin therapy for diabetes will expand
Exploding patient numbers mean that insulin use will increase — as will varieties of insulin, methods of administration, and dosage algorithms.
PCORI approves funding for hepatitis C research
The Patient-Centered Outcomes Research Institute (PCORI) recently approved funding for up to four large studies comparing different approaches to treating hepatitis C. The institute also approved funding for phase II of National Patient-Centered Clinical Research Network (PCORnet).
Drug shortages continue; hospitals cope
Over the last few years, the number of drugs on shortage has remained the same. It may even have gone up. Hospitals continue to confront the issues and devise responses.
Social media and pharmacy: 6 tips on best practices
Pharmacies that don't use social media will soon go the way of the dinosaur. Here are six tips for making these modalities work for you.
New CMS rules for diabetes testing supplies stymie community pharmacies
CMS' new rules for fees, mail order, and delivery of diabetes testing products have created big challenges for patients and the community pharmacists who used to deliver their supplies.
The patient-centered medical home
As a healthcare model, the PCMH is a work in progress, but all signs point to its increasing importance. And pharmacists are key members of the team.
MTM: Centering the pharmacist in healthcare
Pharmacists assume many roles in medication therapy management — roles that are receiving acknowledged provider status
Mobile apps for managing health
Smartphones do more than keep you in contact with friends and family. A slew of apps can help both you and your patients manage health better
At-home diagnostics market still shows healthy growth
According to the numbers, at-home test kits are going to continue to be an area of market growth.
Cetuximab as an add-on to leucovorin, fluorouracil, and oxaliplatin for stage 3 colon cancer adds no benefit
A new study seems to indicate that adding cetuximab to the standard therapy for resected stage 3 colon cancer provides no additional benefits.